7 patients in mono had an average of .4 copies per ml and 7 out of 10 patients in combo were <1. With CD4 memory cells having a half life of 44 months and the longest length of time for patients 48 months we may have not seen the full potential of Leronlimab yet.

In addition the depletion of CD4 cells switches HIV from CCR5 tropic to CXC4 tropic. Leronlimab boosts CD4 survival. Which may inhibit the progression to CXC4.